BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Tocagen Inc. Presents Updated Interim Survival Data From Ongoing Clinical Studies At American Association Of Neurological Surgeons (AANS)/Congress Of Neurological Surgeons (CNS) Section On Tumors

  May 4, 2015

   · 

  6 min read
• Pharm Country

  EcoScience Corporation Significantly Reduces Number Of Outstanding Common Stock

  May 4, 2015

   · 

  3 min read
• Drug Development

  Veloxis Pharmaceuticals A/S Release: Envarsus XR Demonstrates Improved Pharmacokinetic Profile In African-American Transplant Recipients

  May 4, 2015

   · 

  6 min read
• Drug Development

  BioLineRx Ltd. Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia

  May 4, 2015

   · 

  7 min read
• Business

  Traverse Biosciences Executes Agreement With Aratana Therapeutics To Advance Development Of TRB-N0224 For The Treatment And Control Of Periodontal Disease In Pets

  May 4, 2015

   · 

  6 min read
• Burcon Nutrascience Corp. Announces Completion Of Over-Subscribed Rights Offering

  May 4, 2015

   · 

  5 min read
• Drug Development

  MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.)'s Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity In Combination With Tyrosine-Kinase Inhibitor In Pre-Clinical Studies

  May 4, 2015

   · 

  6 min read
• Business

  Cesca Therapeutics Announces Changes In Management

  May 4, 2015

   · 

  3 min read
• China Cord Blood Corporation Receives Notice Of A Transaction Regarding Its 7% Senior Convertible Notes Due 2017 Held By KKR

  May 4, 2015

   · 

  3 min read
• Genetown

  Lantheus Medical Imaging’s First Phase 3 Study Of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 Data Show Statistically And Clinically Significant Improvements

  May 4, 2015

   · 

  9 min read